The present invention relates to the biomedical sector of the treatment of lung diseases and related symptoms. In particular, the present invention provides compositions and methods based on the use of selected polymeric biomaterials, in combination with stem cells and/or their secretome, capable of synergistically improving the development, regeneration and repair of chronic lung injuries and related symptoms. The present invention concerns a new biomaterial comprising: (a) hyaluronic acid having a molecular weight between 100 and 500 KDa; (b) collagen; (c) human mesenchymal cells and/or their secretome, and their use in the treatment of lung diseases, in particular chronic obstructive pulmonary disease (COPD), asthma, idiopathic pulmonary fibrosis (IPF) and pulmonary bronchodysplasia (BPD ) of premature infants.
Current pharmacological therapies for lung diseases only allow a palliative effect with a consequent lack of resolution of lung lesions. So far no one has proposed treating acute and chronic lung diseases with a single product, based on stem cells and/or their secretome and biomaterials, physiological constituents of the pulmonary extracellular matrix, such as collagen and hyaluronic acid, which have the ability to treat the symptoms and even reverse the injury of the lung tissues so as to halt the progression of the disease. Both adult and neonatal patients suffering from acute and chronic lung diseases such as chronic obstructive pulmonary disease (COPD), asthma, idiopathic pulmonary fibrosis (IPF) and pulmonary bronchodysplasia (BPD) of the premature newborn, SARS pneumonia could benefit from the medical device developed from this idea Covid 19. Furthermore, national and international industries involved in biomedical sectors could benefit from expanding their market.
PCT